secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000784199-24-000234
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion Q3 revenue $95.8M (+9% YoY); EBITDA $17.7M (+28%); guides FY $389-396M
-------------------------------------------------------------------------------

- Revenue $95.8M (+9% GAAP, +10% constant currency); net loss ($2.3M) ($0.05 EPS) vs ($9.8M) ($0.24) prior year.
- Non-GAAP net income $5.0M ($0.12 EPS) vs $0.7M ($0.02); includes $2.4M foreign currency gains.
- Adjusted EBITDA $17.7M (+28%); FY guidance narrowed to $389-396M revenue and $69-72M EBITDA.
- On-X +15%, BioGlue +14%, stent grafts +12%; APAC +23% and LatAm +21% (constant currency +32%).
- Regulatory milestones: AMDS PMA module submitted, BioGlue approved in China, NEXUS TRIOMPHE enrollment complete.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419924000234/0000784199-24-000234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419924000234/aort-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000784199-24-000234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer